1Toyama T,Hoshizaki H,Kasama S,et al.Low-dose and long-term G-CSF treatment can improve severe myocardial ischemia in patients with severe coronary artery disease[J].J Nucl Cardiol,2011,18(3):463-471.
2Zhao CP,Xie ZH,Wang P,et al.Granulocyte-colony stimulating factor protects memory impairment in the senescence-accelerated mouse(SAM)-P10[J].Neurological Research,2011,33(4):354-359.
3Franzke A,Piao W,Lauber J et al.G-CSF as immune regulator in T cells expressing the G-CSF receptor:implications for transplantation and autoimmune diseases[J].Blood,2003,102(2):734-739.
4Toh HC,Sun L,Soe Y et al.G-CSF induces a potentially tolerant gene and immunophenotype profile in T cells in vivo[J].Clin Immunol,2009,132(1):83-92.
5Anderlini P.Effects and safety of granulocyte colonystimu-lating factor in healthy volunteers[J].Curr Opin Hematol,2009,16(1):35-40.
6Da Silva N,Meyer-Monard S,Menot ML,et al.G-CSF ac-tivates STAT pathways in Kasumi-1myeloid leukemic cells with the(8;21)translocation:basis for potential therapeutic efficacy[J].Cytokines Cell Mol Ther,1997,3(2):75-78.
7Chang YJ,Zhao XY,Huo MR,et al.Expression profiles of adhesion molecules on naive T cells in bone marrow grafts of healthy donors treated with granulocyte colony-stimulat-ing factor[J].Transpl Immunol,2009,21(4):228-233.
8Donnenberg VS,O’Connell PJ,Logar AJ,et al.Rare event analysis of circulating human dendritic cell subsets and their presumptive mouse counterparts[J].Transplantation,2001,72(12):1946-1951.
9Jun HX,Jun CY,Yu ZX.In vivo induction of T-cell hy-poresponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor[J].Haematologica,2004,89(12):1517-1524.
2Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with hone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol,2005, 23:5074-5087.
3Przepiorka D. Grading and management of graft-vs-host disease// Laughlin M J, Lazarus HM. Allogeneic stem cell transplantation. Totowa : Humana Press Inc,2003:237-260.
4Kroger N, Renges H, Sonnenberg S, et al. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant, 2002, 29: 727-730.
5Mohty M,Bilger K,Jourdan E,et al. Higher doses of CD34 + peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia,2003,17:869-875.
6Cottler-Fox MH, Lapidot T, Petit I, et al. Stem cell mobilization. Hematology Am Soc Hematol Educ Program ,2003:419-437.
7Cao TM, Wong RM, Sheehan K, et al. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol,2005 ,33 :279-285.
8Stanzani M,Martins SL,Saliba RM,et al. CD25 expression on donor CD4 + or CD8 + T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood ,2004,103 : 1140-1146.
9Clark F J, Gregg R, Piper K,et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4 + CD25 high regulatory T cells. Blood ,2004,103:2410-2416.
10Ikebuchi K,Clark SC,Ihle JN.Granulocyte colony-stimulating factor enhances interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.Proc Natl Acad Sci U S A,1998,85:3445-3449.
